Matthew K. Fust, Director at Atara Biotherapeutics, Inc. (ATRA), sold 13,354 shares at $19.50 ($260K) on 2021-11-04, disclosed to the SEC on 2021-11-05.
Seasonal sale ($260k) by Director — this insider has traded ATRA in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |